Merck Seeks European License For Cladribine for relapsing remitting MS

Main Category: Multiple Sclerosis
Also Included In: Neurology / Neuroscience;  Regulatory Affairs / Drug Approvals
Article Date: 27 Jul 2009 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS.

The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington.

If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS.

Source
Multiple Scleroris Society